D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...
4D Molecular Therapeutics (4DMT) released positive interim 1.5- to 3.5-year data from the phase 1/2 PRISM clinical trial ...
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...
GlobalData on MSN
Kodiak reports follow-up outcomes from APEX study of KSI-101
Kodiak Sciences has announced follow-up outcomes from the APEX study, which showed sustained clinical effect of KSI-101 ...
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Asianet Newsable on MSN
FDMT Stock Gains Pre-Market After Positive Study Data For Experimental Drug In Eye Disease
The drug showed maintenance of visual acuity, control of retinal anatomy, and reduction of treatment burden at all time ...
In this system, the implanted computer chip would not just sit on the brain, but become part of the brain. Using a technology ...
Koya Medical ("Koya"), an emerging medtech innovator advancing patient-centered solutions in vascular health, has announced its participation in the Stifel 2025 Healthcare Conference on Thursday, ...
Golden Helix, Inc. announced the release of VarSeq 3 and VSWarehouse 3, the company's next-generation platform for secondary and tertiary genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback